MICHAEL SCOTT: Open Payments
NPI 1063058931 · MANCHESTER, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$47,000 in 145 payments from 9 companies in 2025. Trend: 2023 $343 · 2024 $468 · 2025 $47,000
Speaker / faculty: $31,001Consulting: $6,750Travel & lodging: $6,656Food & beverage: $2,593
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 59 | $29,857 |
| ABBVIE INC. | 55 | $16,238 |
| Axsome Therapeutics, Inc. | 15 | $501 |
| Lundbeck LLC | 6 | $115 |
| Biogen, Inc. | 1 | $100 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: INGREZZA, VRAYLAR, Auvelity, REXULTI, ZURZUVAE, FANAPT, COBENFY, TRINTELLIX.
Industry payments across NH — which companies pay providers there.
